Abstract
June 2016 marks 1 full year since the optional implementation of US Module 1 Specification v2.3. Since its release, pharma companies have dealt with expanded submission-level metadata fields, the ability to submit advertising and promotional submissions, and more rigid validation criteria. Prior to transitioning, sponsors must ensure their building and validating tools are up-to-date, that a system is in place to integrate departments working together for the first time, and that all guidance documents are understood and implemented. Sponsors now can group submissions across application types, which will help save rework across submissions. Looking at one submission type now accepted in eCTD, this paper will explore the new functionality that has created new possibilities and challenges for Regulatory Operations.
Get full access to this article
View all access options for this article.
